Immunovia AB's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 57.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 30.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -11.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Immunovia AB's EBIT per Share or its related term are showing as below:
IMMVF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -94.1 Med: -35.3 Max: 57.4
Current: 57.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Immunovia AB was 57.40% per year. The lowest was -94.10% per year. And the median was -35.30% per year.
IMMVF's 3-Year EBIT Growth Rate is ranked better than 88.76% of 169
companies
in the Medical Diagnostics & Research industry
Industry Median: 13
vs IMMVF: 57.40
Immunovia AB's EBIT for the
three
months ended in Mar. 2026 was $-1.98 Mil.
Immunovia AB (OTCPK:IMMVF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Immunovia AB EBIT per Share Related Terms
Immunovia AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Immunovia AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB (IMMVF) has a EBIT per Share of $-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Immunovia AB and its competitors. According to the industry distribution chart, Immunovia AB ranks #19 out of 169 companies in the Medical Diagnostics & Research industry, placing it in the top 11.2%.
Is Immunovia AB's EBIT per Share too high?
Immunovia AB's current EBIT per Share is $-0.02. Based on the distribution chart, Immunovia AB ranks #19 out of 169 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovia AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #19 out of 169 companies for EBIT per Share. This places Immunovia AB in the top 11% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.00, based on 169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current EBIT per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current EBIT per Share of $-0.02. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current EBIT per Share is $-0.02. Immunovia AB's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current EBIT per Share is $-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
EBIT per Share: $-0.02
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
44GF Score
Get the complete analysis for IMMVF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
